Pseudomonas aeruginosa infection - Pipeline Insight, 2024

This “Pseudomonas aeruginosa infection - Pipeline Insight, 2024,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Pseudomonas aeruginosa infection pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Pseudomonas aeruginosa infection Understanding

Pseudomonas aeruginosa infection: Overview

Pseudomonas aeruginosa infection is caused by bacterium Pseudomonas, a gram-negative bacterium commonly found in the environment e.g., in soil, water, and other moist places. Pseudomonas are opportunistic bacteria which infect individuals who have weak immune system. These bacteria are predominantly responsible for nosocomial infections. Pseudomonas aeruginosa causes urinary tract infections, respiratory system infections, dermatitis, soft tissue infections, bacteremia, bone and joint infections, gastrointestinal infections and a variety of systemic infections, particularly in patients with severe burns and in cancer and AIDS patients who are immunosuppressed. Diagnosing Pseudomonas aeruginosa infection requires laboratory assessments of body fluids such as blood, pus, and urine. Pseudomonas aeruginosa infection can be treated by administration of commonly used antibiotics for instance, gentamicin, tobramycin, and others. However, emergence of multi-drug resistance bacterial strain has made the treatment difficult.

Pseudomonas aeruginosa infection - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Pseudomonas aeruginosa infection pipeline landscape is provided which includes the disease overview and Pseudomonas aeruginosa infection treatment guidelines. The assessment part of the report embraces, in depth Pseudomonas aeruginosa infection commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Pseudomonas aeruginosa infection collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Pseudomonas aeruginosa infection R&D. The therapies under development are focused on novel approaches to treat/improve Pseudomonas aeruginosa infection.

Pseudomonas aeruginosa infection Emerging Drugs Chapters

This segment of the Pseudomonas aeruginosa infection report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Pseudomonas aeruginosa infection Emerging Drugs

AP PA02: Armata Pharmaceuticals Armata’s lead drug candidate, AP PA02, is a therapeutic phage cocktail that targets the pathogen P. aeruginosa, to treat serious respiratory infections, with an initial emphasis on cystic fibrosis (CF) patients. Currently, the drug is in phase I b/II trial and is being tested for its tolerability, and safety among humans.

AB 569: Archs Biopharma Arch’s “novel” drug AB 569 is currently being evaluated for the treatment of antibiotic resistant bacterial infection primarily in the lungs caused by P. aeruginosa. The drug has been designated with orphan drug status and follows a different mechanism of action to treat mucoid and non-mucoid pulmonary P. aeruginosainfections.

Pseudomonas aeruginosa infection: Therapeutic Assessment

This segment of the report provides insights about the different Pseudomonas aeruginosa infection drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Pseudomonas aeruginosa infection

There are approx. 10+ key companies which are developing the therapies for Pseudomonas aeruginosa infection. The companies which have their Pseudomonas aeruginosa infection drug candidates in the most advanced stage, i.e. phase I/ II include, Amrata Pharmaceuticals.

Phases

This report covers around 10+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Pseudomonas aeruginosa infection pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• intravitreal
• Subretinal
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Pseudomonas aeruginosa infection: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Pseudomonas aeruginosa infection therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Pseudomonas aeruginosa infection drugs.

Pseudomonas aeruginosa infection Report Insights

• Pseudomonas aeruginosa infection Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Pseudomonas aeruginosa infection Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Pseudomonas aeruginosa infection drugs?
• How many Pseudomonas aeruginosa infection drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Pseudomonas aeruginosa infection?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Pseudomonas aeruginosa infection therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Pseudomonas aeruginosa infection and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Amrata Pharmaceuticals
• Archs Biopharma
• Qpex Biopharma
• Polyphor
• Nosopharm
• Pfizer

Key Products

• AP PA02
• AB 569
• QPX7728
• Murepavadin
• NOSO A4
• PF-06482077

This product will be delivered within 2 business days.